KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Working Capital Changes (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Other Working Capital Changes for 11 consecutive years, with -$912000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 418.18% to -$912000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$397000.0 through Dec 2025, up 92.49% year-over-year, with the annual reading at -$397000.0 for FY2025, 92.49% up from the prior year.
  • Other Working Capital Changes hit -$912000.0 in Q4 2025 for CRISPR Therapeutics AG, down from $2.2 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $19.0 million in Q3 2021 to a low of -$16.0 million in Q2 2023.
  • Historically, Other Working Capital Changes has averaged -$873000.0 across 5 years, with a median of -$824000.0 in 2025.
  • Biggest YoY gain for Other Working Capital Changes was 12882.55% in 2021; the steepest drop was 12034.09% in 2021.
  • Year by year, Other Working Capital Changes stood at -$4.9 million in 2021, then soared by 82.81% to -$836000.0 in 2022, then plummeted by 671.53% to -$6.4 million in 2023, then surged by 97.27% to -$176000.0 in 2024, then plummeted by 418.18% to -$912000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for CRSP at -$912000.0 in Q4 2025, $2.2 million in Q3 2025, and -$892000.0 in Q2 2025.